Health Canada grants NOC for Biocon Biologics’ Yesintek and Yesintek I.V
Biocon Biologics receives Canadian approval for ustekinumab biosimilars for autoimmune conditions
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
YESINTEK
Biocon Biologics gains market access coverage for Yesintek in the US
Yesintek is a biosimilar to Stelara (ustekinumab) and is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque…
Biocon Biologics announces positive results from Phase 3 Study of Yesintek biosimilar to Ustekinumab…
The safety profile of YESINTEK was similar to the reference product Stelara (Ustekinumab) throughout the duration of the study
Biocon Biologics launches YESINTEK, a Stelara biosimilar, in the United States
Biocon Biologics enters US market with YESINTEK, offering treatment options for Crohn’s disease, ulcerative colitis, plaque…
Biocon Biologics’ Ustekinumab Biosimilar receives positive CHMP opinion
YESINTEK recommended for approval to treat psoriasis, psoriatic arthritis, and Crohn’s disease in adults and children